Copyright
©The Author(s) 2024.
World J Diabetes. Mar 15, 2024; 15(3): 361-377
Published online Mar 15, 2024. doi: 10.4239/wjd.v15.i3.361
Published online Mar 15, 2024. doi: 10.4239/wjd.v15.i3.361
Name | Molecular formula | Number of amino acids | Recommended initial dosage | Recommended dosage for prediabetes | Ref. |
Exenatide | C149H234N40O47S | 39 | 10 μg/day | 10-20 μg/day | Tavlo et al[51] |
Liraglutide | C172H265N43O51 | 9 | 0.6-1.2 mg/day | 3 mg/day | le Roux et al[34] |
Dulaglutide | C40H50N8O5 | 8 | 0.75 mg/week | – | – |
Lixisenatide | C215H347N61O65S | 44 | 10 μg/day | – | – |
Polyethylene glycol loxenatide | C210H325N55O69S(C2H4O)2n | 38 | 0.1 mg/week | – | – |
Benarutide | C149H225N39O46 | 29 | 0.3 mg/day | – | – |
- Citation: Ping WX, Hu S, Su JQ, Ouyang SY. Metabolic disorders in prediabetes: From mechanisms to therapeutic management. World J Diabetes 2024; 15(3): 361-377
- URL: https://www.wjgnet.com/1948-9358/full/v15/i3/361.htm
- DOI: https://dx.doi.org/10.4239/wjd.v15.i3.361